$13.170
-0.637 (-4.84%)收盘时
AGMB 同业对比
In the context of the broader market, AGMB competes directly with industry leaders such as CRMD and VSTM. With a market capitalization of $651.06M, it holds a significant position in the sector. When comparing efficiency, AGMB's gross margin of N/A stands against CRMD's 75.66% and VSTM's 89.92%. Such benchmarking helps identify whether Agomab Therapeutics NV is trading at a premium or discount relative to its financial performance.
Agomab Therapeutics NV 财务表现
Agomab has a negative EPS of -0.71 for Q3 2024 and a forward P/E ratio of 0, indicating it is not yet profitable but is investing in future growth through clinical trials.
Financials
FY2025Q4
YoY:
+38.56%
-16.62M
Operating Profit
FY2025Q4
YoY:
+48.32%
-17.40M
Net Income after Tax
FY2025Q4
YoY:
+50.00%
-0.36
EPS - Diluted
FY2025Q4
YoY:
+2.93%
-13.18M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。